Partial replicate design and FDA ABE code [RSABE / ABEL]

posted by d_labes  – Berlin, Germany, 2010-04-28 11:47 (5907 d 11:45 ago) – Posting: # 5252
Views: 41,961

Hi Dave,

❝ ❝ D. Labes:

❝ ❝ BTW: What is missing is explicit code for ABE evaluation for the partial replicate design ...


❝ The explicit code for this is on the last page (page 9) of the progesterone guidance. It's just the unscaled approach. You can use that method for both 4-period and 3-period designs.

(underlined by me)

I do not believe that. We have experimented with the FDA code on partial replicate design here in the forum and got some strange results. See f.i. here and here.
IMHO this is due to the fact that the intra-subject variance for Test is not identifiable in this design.


BTW: Regarding the sample size question of my very dear friend KR have a look into this tread.

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,571 registered users;
320 visitors (0 registered, 320 guests [including 15 identified bots]).
Forum time: 23:33 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5